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Abstract
Introduction: Despite intense interest in trial registration, there is a wide gap between theoretical postulates
on trial registration and its implementation worldwide.
Objective: We aimed to evaluate trialists views about current international guidelines on trial registration,
including the World Health Organization's (WHO) International Clinical Trials Registry Platform (ICTRP) policies
and the Ottawa Statement, as well as their intention to register any future clinical trials they conduct.
Methods: We identified all 40,158 PUBMED-indexed clinical trials published from May 2005 to May 2006 using
an advanced search strategy. From a random sample of 500 confirmed clinical trials, corresponding authors with
e-mail contact addresses were surveyed.
Results: A total of 275 (60%) questionnaires from 45 countries were completed. 31% of the respondents had
received only nonindustry funding during the past ten years, while 5% and 61% had received only industry or
mixed funding respectively. Approximately two third of participants supported registration of all 20 WHO Data
Set items, and endorsed the Ottawa Statement part 1 and part 2. Delayed public disclosure of some essential data
in instances where they may be considered sensitive for competitive commercial reasons was supported by 30%
of the participants, whereas immediate disclosure was supported by 53%. Only 21% of participants had registered
all of their ongoing trials since 2005, while 47% stated that they would provide the 20 WHO Data Set items to a
publicly accessible register for all their future clinical trials; a significantly higher proportion of participants who
received only nonindustry funding (62%) was found among those who would always provide the 20 WHO items
for future trials, compared to 42% of participants who received mixed or only industry funding. Among those who
were undecided about endorsing registration. One third of participants expressed a lack of sufficient knowledge
as the primary reason.
Conclusion: Although disagreement was apparent on certain issues, our findings illustrate that trial registration
is gradually becoming part of the current research paradigm internationally. Our results also suggest that
researchers require more knowledge to inform their decision to comply with the International standards at this
early stage of voluntary trial registration.
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Background
Over the past few years, several key initiatives have ena-
bled substantial progress in the public registration of clin-
ical trials worldwide. Major registers such as
ClinicalTrials.gov and Controlled Clinical trials-ISRCTN
have been recording trial protocol information since
2000, and the number of registered trials increased dra-
matically in 2005 after the requirement for registration
was introduced by several medical journals, led by the
International Committee of Medical Journal Editors
(ICMJE) [1,2]. The World Health Organization's Interna-
tional Clinical Trials Registry Platform (WHO ICTRP) is
currently leading international efforts to implement glo-
bal standards for trial registration and results reporting [2-
4]. Based on both ethical and scientific reasons for trial
registration, WHO is urging investigators, research institu-
tions and companies to register all trials that prospectively
test the effects of healthcare interventions on humans.
Furthermore, the Ottawa Group, an international group
of individuals and organizations from the international
medical research community, developed two consensus
documents – the Ottawa Statement Part 1 on the princi-
ples of trial registration, and the Ottawa Statement Part 2
on the principles of its implementation The Ottawa group
supported the WHO initiative as a good initial step, but
called for more details of trial protocols to be prospec-
tively registered [5-7]. The Institute of Medicine report
endorses the ICJME requirement to prospectively register
clinical trials as a condition for publication, as well as the
pharmaceutical industry's commitment to register and
post clinical trials results [8].
Nevertheless, despite intense interest in this topic in
recent years, there is a wide gap between theoretical pos-
tulates on trial registration and its implementation world-
wide. This gap may be due to differing interests of the
various stakeholders involved, including researchers,
patients, pharmaceutical industry, funders, governments,
registries, bio-medical journal editors, and the public [9-
11]. One of the biggest barriers to comprehensive trial reg-
istration is the lack of awareness by researchers about the
importance of the problem [9]. According to the Ottawa
Statement part 1, "the principal investigator has a respon-
sibility to ensure that the sponsor(s) obtains a Unique
Identification number and registers his or her contact
information, the protocol information and the trial
results" [5].
Although there is general agreement about the type of pro-
tocol information that should be registered for a trial, as
defined by the 20-item WHO Registration Data Set (Table
1) [11,1], controversy surrounded issues related to regis-
tration of key versus all secondary outcomes, as well as
immediate versus delayed disclosure of 5 protocol items
that were felt to be commercially sensitive by industry for
some trials (study interventions, scientific title, sample
size, primary and secondary outcomes) [10]. Industry has
offered, instead, to consign these five hidden items to a
locked electronic depository that is publicly inaccessible
until the information is no longer deemed commercially
sensitive [10]. Regarding results reporting on trial registra-
tion, the principles expressed in the Ottawa Statement 1
read "At a minimum, results for outcomes and analyses
specified in the protocol (as approved by the IRB/IEC), as
well as data on harms, should be registered regardless of
whether or not they are published. If a trial is terminated
prematurely, any available results should be registered
along with the reason for termination." [5,6]. However,
the Ottawa Group stated that researchers should have suf-
ficient time to publish their findings before the registered
results are released for public [5].
The aim of our study is to evaluate trialists' views about
the global standards proposed by WHO and the Ottawa
Statements, as well as their intention to register any future
clinical trials they conduct.
Materials and methods
We used PUBMED to identify a sample of investigators
authoring clinical trial reports published from May 2005
to May 2006. The structured search filter included the fol-
lowing terms: "Randomized controlled trial" [PT] OR
"controlled clinical trial" [PT] OR "randomized control-
led trials" [MeSH] OR "random allocation" [MeSH] OR
"double-blind method" [MeSH] OR "single-blind
method" [MeSH] OR "clinical trial" [PT] OR "clinical tri-
als" [MeSH] OR "clinical trial" [TW] OR "randomized
trial" [TW] OR "randomised trial" [TW]. The strategy
focused on humans studies and was not limited by lan-
guage or type of intervention.
For this exploratory survey, we identified 40,158 refer-
ences, from which a random sample of 500 clinical trials
with e-mail contact addresses was selected. Titles and
abstracts identified from the sample were screened by one
reviewer (LR). A previous study showed that approxi-
mately 25% of articles found by the search are clinical tri-
als and cite the e-mail of one author [12]. The sample size
was calculated assuming that 5% of emails would not
reach their intended recipient. In addition, Web-based
surveys have variable response rates (9 to 96%), depend-
ing on the topic, methods and participants [13,14]. The a
priori  response rate was estimated to be 75%. In the
absence of previous data, we estimated the proportion of
trialists who would endorse registration to be 50%, yield-
ing a sample size of 500 with a 95% confidence interval of
-5% to 5%. The primary outcomes of our study were the
proportion of trialists endorsing the following principles:
trial registration overall, registration of all secondary out-Trials 2007, 8:30 http://www.trialsjournal.com/content/8/1/30
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comes, immediate public disclosure of registered protocol
items, and public disclosure of trial results.
The survey was piloted on 50 participants. For the full
sample, each participant was sent a survey by email con-
taining links to the WHO ICTRP and the Ottawa Group
websites [see Additional file 1]. Up to four reminders were
sent. We collected the following information: country of
origin, gender, age, type of funding for clinical trials over
the past 10 years, main research institution, number of
ongoing trials, proportion of ongoing trials registered in
public databases, knowledge and support for the WHO
Registration Data Set, as well as attitudes towards the
Ottawa Statements (part 1 and part 2), registration of key
versus all secondary outcomes, timing of public disclosure
of protocol items, and disclosure of trial results.
Data were analyzed using SPSS 12.0. Chi-square tests were
used to determine associations between categorical varia-
bles.
Results
Demographic data
Out of 500 e-mail questionnaires, forty-two (8%) email
addresses were invalid (bounced back or out-of-office
autoreply). We received 275/458 (60%) replies from 45
countries. The median age of participants was 45 years
(10th-90th percentiles: 33 – 57) and 70% were men. The
Table 1: Minimum data set that should be recorded for clinical trial registration, according to the International Standards launched by 
the World Health Organization, in 2006 (items felt to be commercially sensitive are highlighted)
Number Item Abbreviated Definition/Explanation*
1. Primary register trial number Name of Primary Register, and the unique ID number assigned by the Primary 
Register to this trial.
2. Trial registration date Date when trial was officially registered in the Primary Register.
3. Secondary IDs Other identifying numbers and issuing authorities besides the Primary Register, if any
4. Source(s) of monetary or material support Major source(s) of monetary or material support for the trial
5. Primary sponsor The individual, organization, group or other legal entity which takes responsibility for 
initiating, managing and/or financing a study.
6. Secondary sponsor(s) Additional individuals, organizations or other legal persons, if any, that have agreed 
with the primary sponsor to take on responsibilities of sponsorship.
7. Contact for public queries Email address, telephone number, or postal address of the contact who will respond 
to general queries, including information about current recruitment status
8. Contact for scientific queries Email address, telephone number, or postal address, and affiliation of the person to 
contact for scientific queries about the trial
9. Public title (of the study) Title intended for the lay public in easily understood language.
10. Scientific title Scientific title of the study as it appears in the protocol submitted for 
funding and ethical review
11. Countries of recruitment The countries from which participants will be, are intended to be, or have been 
recruited.
12. Health condition or problems studied Primary health condition(s) or problem(s) studied
13. Intervention(s) Specific name of the intervention(s) and the comparator/control(s) being 
studied
14. Key inclusion and exclusion criteria Inclusion and exclusion criteria for participant selection, including age and sex.
15. Study type A single arm study is one in which all participants are given the same intervention. 
Trials in which participants are assigned to receive one of two or more interventions 
are NOT single arm studies. Crossover trials are NOT single arm studies.
A trial is "randomized" if participants are assigned to intervention groups using a 
method based on chance (e.g., random number table, random computer-generated 
sequence, minimization, adaptive randomization).
16. Date of the first enrollment (anticipated or 
actual date of the enrollment of the first study 
participant)
If the trial is being registered after recruitment of the first participant record actual 
date of Anticipated date of enrollment of the first participant.
17. Target sample size Number of participants that this trial plans to enroll.
18. Recruitment status Recruitment status of the trial.
19. Primary outcome(s) Outcomes are events, variables, or experiences that are measured 
because it is believed that they may be influenced by the intervention. The 
Primary Outcome should be the outcome used in sample size 
calculations, or the main outcome(s) used to determine the effects of the 
intervention(s).
20. Key secondary outcomes Secondary outcomes are events, variables, or experiences that are of 
secondary interest or that are measured at timepoints of secondary 
interest.
* Full items definition and/or explanation can be viewed in the International Clinical Trials Registry Platform (ICTRP) website (25).Trials 2007, 8:30 http://www.trialsjournal.com/content/8/1/30
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largest number of respondents was from the United States
(15%), Italy (9%), United Kingdom (6%), France (5%)
and Germany (5%). However 20% of participants did not
include their country of origin in the survey, which made
the evaluation of response rate by country difficult.
Of the 275 (60%) survey respondents, 31% received only
non-industry funding over the past ten years (Table 2).
Type of funding reported by participants was significantly
different between women and men; 44% of women
received non industry funding compared to 27% of men
while 50% and 68% received mixed funding and 6% and
5% received only industry funding respectively (X2 = 7.82;
DF 2, p = 0.02). Most respondents were based at an aca-
demic or hospital institution (Table 2).
Trial registration issues
One third of trialists stated that they were experts or very
knowledgeable about issues related to trial registration,
while 56% reported having mild to moderate knowledge;
12% reported having no relevant knowledge.
64% of investigators supported registration of all 20 items
of the WHO Data Set, while 6% did not support any. 65%
and 63% already had or planned to endorse the Ottawa
Statements (part 1 and part 2) respectively; 3% and 3%
did not support the statements, while 31% and 34%
respectively were undecided. The attitudes of respondents
were similar regarding the Ottawa Statements and the
WHO standards.
Ninety-five trialists (35%) believed that all secondary trial
outcomes should be registered and disclosed, whereas
139 (51%) stated that only key secondary outcomes
should be registered and disclosed. With regards to timing
of disclosure for five essential data items (Scientific title,
Intervention(s), Target sample size, Primary outcome(s),
and Key secondary outcomes) in instances where they
may be considered sensitive for competitive reasons, no
delayed disclosure was supported by 53% of trialists while
31% supported delayed disclosure Among those who
agreed with delayed disclosure in some cases, most con-
sidered that undisclosed items should be made publicly
available upon trial completion or upon regulatory
approval (Figure 1). The Ottawa Group position with
regards to registration of trial results was completely or
mostly supported by 61% of participants, while 10% were
not supportive at all.
The median number of ongoing clinical trials per
respondent was 3 (10th-90th percentile range: 0 – 7).
Only 21% of participants had registered all of their ongo-
ing trials. In addition only 47% of respondents stated that
they would provide all 20 items of the WHO Data Set to a
publicly accessible register for future clinical trials.
Between respondents receiving only non-industry fund-
ing compared to those receiving only industry or mixed
funding, there were no significant differences for the pro-
portion endorsing trial registration overall, registration of
secondary outcomes, delayed disclosure of protocol
items, or results registration. A significantly higher pro-
portion of participants who received only nonindustry
funding (62%) was found among those who would
always provide the 20 WHO items for future trials, com-
pared to 42% of participants who received mixed or only
industry funding (X2 = 8.59; df 1, p = 0.0034).
57% of participants did not provide their names; no sig-
nificant difference regarding registration of future trials
was found among anonymous respondents compared to
those who included their names (X2 = 12.4; df 7, p =
0.087). However more women (70%) were anonymous
compared to men (47%) (X2 = 6.03; df 1, p = 0.014).
Summary of trialists' concerns regarding trial registration
We received a wide range of open comments. Common
concerns were expressed related to (a) the lack of time to
Table 2: Characteristics of respondents N = 275
Total Women
n = 82
30%
Men
n = 193
70%
Source of trial funding received over 
the past ten years
Only nonindustry 85 (31%) 44% 27%
Only industry 14 (5%) 6% 5%
Mixed 168 (61%) 50% 68%
No response 8 (3%)
Main institution of respondents Academic 154 (56%)
Hospital 90 (33%)
Governmental 6 (2%)
Industry (eg. pharmaceutical, device, biologics, etc) 3 (1%)
Other type 14 (5%)
No response 8 (3%)Trials 2007, 8:30 http://www.trialsjournal.com/content/8/1/30
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complete "bureaucratic" tasks (4%), (b) the possibility
that registration of early (phase I) trials could deter
research as their results may be misinterpreted (2%), and
(c) that the results of poorly-designed trials might be con-
fusing (1%). Three trialists expressed concern that the
Ottawa Statement or the WHO initiative offers no protec-
tion from other competing investigators who may copy
the trial, recruit faster and publish sooner. In addition,
they mentioned the administrative burden of handling
additional public queries as well as contractual obliga-
tions to sponsors would be difficult to handle. Other par-
ticipants stated that some countries have limited internet
access, and that registration should be a tool for protecting
the patient's rights rather than yet another means of over-
burdening researchers.
Discussion
Main findings
Our survey provides useful information about trialists'
attitudes towards clinical trial registration. Although more
than 60% of respondents support both the WHO 20-item
Data Set and the Ottawa Statements (parts 1 and 2), only
47% declared that they would always provide the WHO
Data Set to a publicly accessible register for future clinical
trials. In addition a third of participants were undecided
regarding trial registration while a small minority rejected
it outright.
The proposal by WHO and the Ottawa Group to submit
protocol information at trial inception as well as results to
a freely accessible public register is a crucial step towards
promoting research transparency. However, countries
have different legal requirements and most do not require
public registration of all clinical trials. They also have
diverse levels of public disclosure of information. For
example all entities conducting clinical trials of experi-
mental treatments for serious or life-threatening condi-
tions or diseases in the United States (US) are required to
submit certain information to the ClinicalTrials.gov regis-
ter, which is a publicly accessible database. However the
US legislation does not include other type of diseases, and
does not require the registration of all 20 items suggested
by WHO. Furthermore, information on Phase I trials of
drugs and devices is not publicly available unless they
have been approved by the US Food and Drug Adminis-
tration [15]. It is evident that there is a need for compre-
hensive legislation on trial registration. Otherwise, when
ongoing or completed trials remain hidden, researchers
may be unknowingly and inappropriately duplicating tri-
als on similar interventions that had already been shown
in previous trials to have serious adverse events or no ben-
efit.
Our survey demonstrated greater support for immediate
rather than delayed disclosure of information submitted
to trial registers (53% vs. 30%), Figure 1. However, some
researchers argue that confidentiality issues and contrac-
tual obligations with sponsors would be difficult to han-
dle if they decided to register all clinical trials in a publicly
accessible register. Some stakeholders also claim that dis-
closure of all 20 WHO data set items may sometimes
endanger proprietary rights. However others argue that
delayed disclosure would facilitate registration of incom-
plete information for a given trial, and hidden trial infor-
mation would not meet ethical and scientific standards
[4,16-18]. In addition, trial participants are already
informed about a given study as part of the informed con-
sent process, and intelligence companies provide detailed
data about pipeline drugs at a cost; thus this information
is not secret [19,20]. Furthermore, informed choice about
which particular trial to join requires that information
about all ongoing trials be available to each potential trial
participant.
A universal requirement for clinical trial registration as a
condition of ethics approval would level the playing field
and address concerns over competitive disadvantage [21].
In the interim, voluntary registration of clinical trial infor-
mation remains an important first step, and dissemina-
tion strategies to inform researchers about trial
registration are thus needed, particularly in developing
countries.
More participants supported registration and disclosure of
only key rather than all secondary outcomes. Use of the
adjective "key" introduces subjectivity in its definition, as
outcomes may be considered as non-key by some
researchers but essential by others.
Position of respondents regarding a delayed disclosure of five  essential protocol items n = 261 Figure 1
Position of respondents regarding a delayed disclosure of five 
essential protocol items n = 261.
33
50
17
12 3
146
No delayed disclosure 56%
Undecided 13%
Acceptable upon trial
completion 19%
Acceptable upon regulatory
approval 7%
Acceptable during the trial
5%
Acceptable when
commercial products is first
marketed 1%Trials 2007, 8:30 http://www.trialsjournal.com/content/8/1/30
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Limitations
Some concerns have been raised regarding Web based sur-
veys including coverage bias or bias due to sampled indi-
viduals not having or choosing not to access the Internet
[22-24]. There was selection bias due to less than half of
the authors having e-mail addresses listed in the publica-
tion. For example there were 8 publications from Russia
but no electronic addresses were available. Furthermore a
substantial percentage of those with valid email addresses
did not respond. There are also limitations related to
PubMed. Although the MEDLINE database indexes more
than 3500 biomedical journals, it excludes many existing
trials and authors worldwide. In addition PUBMED may
be biased toward English-language journals and has
poorer coverage of European journals than compared to
other databases. Considering that 74% of respondents
were from non-English speaking countries, there was
unlikely to be language bias from the survey being in Eng-
lish.
It should also be noted that there were few participants
from commercial or government institutions.
At the same time, participants who had some knowledge
about trial registration may have been more able to
respond. It is highly probable that a number of respond-
ents may have needed more knowledge about trial regis-
tration to answer specific questions, although we
provided links to relevant information on the Internet.
It is disappointing that although 64% of participants
endorsed trial registration, only 47% stated that they
would always provide at least all 20 WHO Data Set items
for future trials. This finding may reflect their concerns
over academic or commercial interests.
Conclusion
Selective reporting of information about ongoing and
completed trials is harmful for society as it violates ethical
and scientific responsibilities, and distorts the body of evi-
dence available for clinical decision-making. Voluntary
registration of clinical trial information is an important
and complex initial step that has the support of almost
half of trialists. Dissemination strategies to inform
researchers about the process and benefits of trial registra-
tion are needed to improve compliance.
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